IOVANCE BIOTHERAPEUTICS, INC.
IOVABiological Products, (No Disgnostic Substances) · Avg daily volume 17.9M · fiscal year ends Dec$14.56−0.06−0.41%Volume 9.1M−49% vs avg
10-day20-day50-day200-dayRS line vs S&P 500▲ earnings filed, EPS vs a year agoQ3 EPS due in ~24 days
2026-10-12O 14.50 H 14.82 L 14.20 C 14.56 (−0.41%)Vol 9.1M10 14.0220 12.1850 9.36200 5.07RS line 1.871RS rating 99
| FY (Dec) | EPS $ | Chg | High | Low |
|---|---|---|---|---|
| 2019 | -1.59 | – | – | – |
| 2020 | -1.88 | −18% | – | – |
| 2021 | -2.23 | −19% | – | – |
| 2022 | -2.49 | −12% | – | – |
| 2023 | -1.89 | +24% | – | – |
| 2024 | -1.28 | +32% | 18 | 7 |
| 2025 | -1.09 | +15% | 8 | 2 |
| TTM | -0.70 | 15 | 2 |
Ratings & facts
RS Rating99
Days at RS 90+21
Setup checks3 / 3
EPS chg, last qtr+67%
EPS accelerating3 qtrs ✓
Sales chg, last qtr+66%
P/E (last 4 qtrs)–
Mkt cap$6.60B
Off 52-wk high-4.8%
Quarterly earnings
Latest filing: 10-Q, 2026-08-06Mar ’24FQ1 ’24
Jun ’24FQ2 ’24
Sep ’24FQ3 ’24
Dec ’24Q4FQ4 ’24
Mar ’25FQ1 ’25
Jun ’25FQ2 ’25
Sep ’25FQ3 ’25
Dec ’25Q4FQ4 ’25
Mar ’26FQ1 ’26
Jun ’26FQ2 ’26
EPS
EPS
−$0.42
−$0.34
−$0.28
−$0.25
−$0.36
−$0.33
−$0.25
−$0.15
−$0.19
−$0.11
% chg
+16%
+28%
+39%
+44%
+14%
+3%
+11%
+40%
+47%
+67%
Sales
715,000
31.1M
58.6M
73.7M
49.3M
60.0M
67.5M
86.8M
71.4M
99.3M
% chg
–
+12,970%
+12,385%
+15,189%
+6,799%
+93%
+15%
+18%
+45%
+66%
Filed
05/09
08/08
11/07
02/27
05/08
08/07
11/06
02/24
05/07
08/06
EPS growth ≥ 25%0–25%fallingno comparison
Source: SEC EDGAR 10-Q and 10-K filings, loaded the first time a stock is opened and refreshed daily. Q4 = full year minus the first three quarters. Growth from a loss is measured against the size of the loss (−$1 → $2 = +300%). Analyst estimates are not in EDGAR.